Loading...
Steroid-sparing agents in giant cell arteritis
Sagdeo, Amol Askari, Ayman Dixey, Josh Morrissey, Hana
Sagdeo, Amol
Askari, Ayman
Dixey, Josh
Morrissey, Hana
Citations
Altmetric:
Editors
Other contributors
Affiliation
Epub Date
Issue Date
2019-07-31
Submitted date
Files
Loading...
TORJ-13-61.pdf
Adobe PDF, 518.58 KB
Alternative
Abstract
Background: Giant cell arteritis is the commonest form of medium-to-large vessel vasculitis, requiring long-term corticosteroid therapy. The short- and long-term side effects of corticosteroids are many, including weight gain, psychological effects, osteoporosis, cardiometabolic complications, and infections. Materials and Methods: Various agents used in place of or in combination with corticosteroids to reduce corticosteroid-related side effects were reviewed. However, considerable variation in practice was identified giving unclear guidance. This review included the most recent evidence on methotrexate, mycophenolate mofetil, azathioprine, cyclophosphamide, abatacept, and tocilizumab Results and Discussion: Also discussed are encouraging results with tocilizumab in GCA patients. Amongst the agents available for steroid-sparing effects, tocilizumab demonstrated the most robust data and is consequently recommended as the agent of choice for steroid-sparing, for remission induction, remission maintenance, and treating relapsing and refractory cases of GCA.
Citation
Sagdeo, A., Askari, A., Dixey, J., Morrissey, H. and Ball, P. (2019) Steroid-sparing agents in giant cell arteritis, The Open Rheumatology Journal, 13, pp. 61-71.
Publisher
Journal
Research Unit
PubMed ID
PubMed Central ID
Embedded videos
Additional Links
Type
Journal article
Language
en
Description
Series/Report no.
ISSN
1874-3129